143 related articles for article (PubMed ID: 31127507)
1. Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.
Connock M; Auguste P; Dussart C; Guyotat J; Armoiry X
J Neurooncol; 2019 Jul; 143(3):605-611. PubMed ID: 31127507
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma.
Bernard-Arnoux F; Lamure M; Ducray F; Aulagner G; Honnorat J; Armoiry X
Neuro Oncol; 2016 Aug; 18(8):1129-36. PubMed ID: 27177573
[TBL] [Abstract][Full Text] [Related]
4. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
[No Abstract] [Full Text] [Related]
5. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
J Neurooncol; 2024 Jun; 168(2):259-267. PubMed ID: 38563851
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Messali A; Hay JW; Villacorta R
Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
[TBL] [Abstract][Full Text] [Related]
8. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
Uyl-de Groot CA; Stupp R; van der Bent M
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Martikainen JA; Kivioja A; Hallinen T; Vihinen P
Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
Roussakow SV
BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
[TBL] [Abstract][Full Text] [Related]
14. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Messali A; Villacorta R; Hay JW
Pharmacoeconomics; 2014 Dec; 32(12):1201-12. PubMed ID: 25085219
[TBL] [Abstract][Full Text] [Related]
15. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
[TBL] [Abstract][Full Text] [Related]
16. Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Guzauskas GF; Salzberg M; Wang BC
CNS Oncol; 2018 Jul; 7(3):CNS23. PubMed ID: 30124334
[TBL] [Abstract][Full Text] [Related]
17. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
18. A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme.
Connock M; Auguste P; Armoiry X
Eur J Health Econ; 2021 Feb; 22(1):89-100. PubMed ID: 33130929
[TBL] [Abstract][Full Text] [Related]
19. Improved cost-effectiveness of short-course radiotherapy in elderly and/or frail patients with glioblastoma.
Ghosh S; Baker S; de Castro DG; Kepka L; Kumar N; Sinaika V; Matiello J; Lomidze D; Dyttus-Cebulok K; Rosenblatt E; Fidarova E; Roa W
Radiother Oncol; 2018 Apr; 127(1):114-120. PubMed ID: 29452901
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
Monz BU; König HH; Leidl R; Staib L; Link KH
Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
